ClassID:

20412

A61K31/4985 - page 5 - CPC Classification

Classification description:

Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring heteroatoms, e.g. piperazine Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems

Recent Application in this class:
#1201
20210093632
2021-04-01

Geranylgeranyltransferase I inhibitor for treatment of a PTEN defective cancer

#1202
20210093600
2021-04-01

Method of determining composition effective for treating diabetes

#1203
20210087204
2021-03-25

BCKDK inhibitors

#1204
20210087198
2021-03-25

sGC STIMULATORS

#1205
20210085677
2021-03-25

SHP2 phosphatase inhibitors and methods of making and using the same

#1206
20210085663
2021-03-25

COMPOSITIONS AND METHODS FOR TREATING CANCER WITH ATYPICAL BRAF MUTATIONS

#1207
20210085657
2021-03-25

Stable pharmaceutical compositions of dihydroergotamine mesylate

#1208
20210079002
2021-03-18

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS

#1209
20210078991
2021-03-18

THERAPEUTIC COMPOUNDS

#1210
20210077485
2021-03-18

Pharmaceutical compositions of nilotinib

#1211
20210070752
2021-03-11

HETEROCYCLIC COMPOUNDS USEFUL AS PDK1 INHIBITORS

#1212
20210069230
2021-03-11

SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES

#1213
20210069188
2021-03-11

Pyrazolo[3,4-b]pyrazine SHP2 phosphatase inhibitors and methods of use thereof

#1214
20210061813
2021-03-04

NOVEL TRICYCLIC COMPOUNDS

#1215
20210061777
2021-03-04

OXAZOLIDINONE COMPOUNDS AND METHODS OF USE THEREOF AS ANTIBACTERIAL AGENTS

#1216
20210060011
2021-03-04

Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

#1217
20210060010
2021-03-04

ORGANIC COMPOUNDS

#1218
20210060009
2021-03-04

Methods of treating acute depression and/or acute anxiety

#1219
20210059993
2021-03-04

COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS

#1220
20210054466
2021-02-25

TUMOR BIOMARKERS AND USE THEREOF

#1221
20210053988
2021-02-25

Substituted 1,4-methanopyrido[1′,2′:4,5]pyrazino[1,2-a]pyrimidines for treating viral infections

#1222
20210053959
2021-02-25

USE OF SELECTIVE GABA A ALPHA 5 NEGATIVE ALLOSTERIC MODULATORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CONDITIONS

#1223
20210052591
2021-02-25

Liquid oral formulations for sildenafil

#1224
20210052581
2021-02-25

Use of tadalafil as protein arginine methyltransferase (PRMT5) inhibitor

#1225
20210046035
2021-02-18

Combination methods and compositions including sleep therapeutics for treating mood

#1226
20210040096
2021-02-11

FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS

#1227
20210038607
2021-02-11

OXADIAZOLYLTHIOPHENE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS

#1228
20210038602
2021-02-11

COMBINATION TREATMENT OF ACUTE MYELOID LEUKEMIA

#1229
20210038598
2021-02-11

Combination of an FGFR inhibitor and a CMET inhibitor

#1230
20210032247
2021-02-04

Pharmaceutical compositions comprising 4-(6Br,10aS)-3-methyl-2, 3, 6b, 9, 10, 10a-hexahydro-1H, 7H-pyrido[3′, 4′, 5] pyrolo[1,2,3-de] quinoxalin-8YL)-1-(4-fluorophenyl)-butane-1-one and methods of treating conditions of the central nervous system

#1231
20210030776
2021-02-04

Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof

#1232
20210030754
2021-02-04

Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor

#1233
20210030753
2021-02-04

Methods, compositions, and uses of novel FYN kinase inhibitors

#1234
20210030728
2021-02-04

Use of gaboxadol in the treatment of diabetes and related conditions

#1235
20210030718
2021-02-04

COMBINATIONS FOR TREATING CANCER

#1236
20210024536
2021-01-28

BCKDK inhibitors

#1237
20210022991
2021-01-28

Oral film formulation for modulating absorption profile

#1238
20210017182
2021-01-21

Heterocyclic inhibitors of PTPN11

#1239
20210015872
2021-01-21

PANCREATIC ENDOCRINE PROGENITOR CELL THERAPIES FOR THE TREATMENT OF OBESITY AND TYPE 2 DIABETES (T2D)

#1240
20210015829
2021-01-21

Substituted pyrrolo[1,2-a]pyrazines and pyrrolo[1,2-a][1,4]diazepines as TREX1 inhibitors

#1241
20210015816
2021-01-21

POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE

#1242
20210009607
2021-01-14

Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect

#1243
20210009592
2021-01-14

ORGANIC COMPOUNDS

#1244
20210009262
2021-01-14

Tetracyclic heterocycle compounds useful as HIV integrase inhibitors

#1245
20210008065
2021-01-14

ORGANIC COMPOUNDS

#1246
20210002280
2021-01-07

NOVEL METHODS

#1247
20210000857
2021-01-07

COMPOSITION REMEDY TO PREVENT SYMPTOMS RELATED TO EXCESSIVE ALCOHOL CONSUMPTION

#1248
20210000822
2021-01-07

NOVEL METHODS

#1249
20200407362
2020-12-31

NOVEL METHODS

#1250
20200405714
2020-12-31

Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer

#1251
20200405713
2020-12-31

METHODS AND COMPOSITIONS FOR SLEEP DISORDERS AND OTHER DISORDERS

#1252
20200400651
2020-12-24

METHOD OF USING HUMAN SPHEROIDS FOR DRUG DISCOVERY

#1253
20200399281
2020-12-24

Pyrazolo[1,5-a]pyrazin-4-yl derivatives

#1254
20200399244
2020-12-24

Therapeutic compounds and uses thereof

#1255
20200397702
2020-12-24

Pharmaceutical compositions

#1256
20200390784
2020-12-17

Modulation of solubility, stability, absorption, metabolism, and pharmacokinetic profile of lipophilic drugs by sterols

#1257
20200390764
2020-12-17

PHARMACEUTICAL FORMULATIONS, PROCESSES FOR PREPARATION, AND METHODS OF USE

#1258
20200385393
2020-12-10

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof

#1259
20200383979
2020-12-10

Triaryl compounds for treatment of PD-L1 diseases

#1260
20200377953
2020-12-03

THERAPEUTIC AND DIAGNOSTIC METHODS FOR MAST CELL-MEDIATED INFLAMMATORY DISEASES

#1261
20200375988
2020-12-03

Transmucosal methods for treating psychiatric and neurological conditions

#1262
20200375987
2020-12-03

METALLO-BETA-LACTAMASE INHIBITORS AND METHODS OF USE THEREOF

#1263
20200375986
2020-12-03

Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors

#1264
20200369683
2020-11-26

Compositions and methods for regulating glucose homeostasis and insulin action

#1265
20200369665
2020-11-26

IMIDAZO[1,2-A]PYRAZINE MODULATORS OF THE ADENOSINE A2A RECEPTOR

#1266
20200368244
2020-11-26

Pulmonary hypertension treatment

#1267
20200368230
2020-11-26

Compositions and methods to protect mammalian tissue against cold and other metabolic stresses

#1268
20200368229
2020-11-26

Methods for Treating HCV

#1269
20200361949
2020-11-19

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

#1270
20200361947
2020-11-19

Bicyclic and tricyclic compounds

#1271
20200360523
2020-11-19

Anti-cancer nuclear hormone receptor-targeting compounds

#1272
20200360384
2020-11-19

Inhibitors of human immunodeficiency virus replication

#1273
20200360294
2020-11-19

Nanoparticle Compositions and Methods for Synthesis Thereof

#1274
20200360290
2020-11-19

Oral compositions and the preparation methods thereof

#1275
20200354358
2020-11-12

Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity

#1276
20200353034
2020-11-12

Pharmaceutical composition for preventing or treating diabetes, containing zinc salt, cyclo-hispro and antidiabetic drug as active ingredients

#1277
20200352949
2020-11-12

Organic compounds

#1278
20200352944
2020-11-12

Therapeutic Compositions

#1279
20200352939
2020-11-12

METHOD OF THERAPEUTIC ADMINISTRATION OF DHE TO ENABLE RAPID RELIEF OF MIGRAINE WHILE MINIMIZING SIDE EFFECT PROFILE

#1280
20200347025
2020-11-05

Compounds and compositions for inhibition of FASN

#1281
20200346186
2020-11-05

Preservative removal from eye drops

#1282
20200345858
2020-11-05

COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ERGOT ALKALOID TOXICITY

#1283
20200345815
2020-11-05

Type I diabetes therapy

#1284
20200345744
2020-11-05

Treatment of tachycardia

#1285
20200345730
2020-11-05

Compositions, devices, and methods for treating or preventing headaches

#1286
20200345729
2020-11-05

Substituted pyrazolo[1,5-a]pyrazines as negative allosteric modulators of group II metabotropic glutamate receptor

#1287
20200345728
2020-11-05

COMPOSITIONS AND METHODS FOR TREATMENT OF ATHEROSCLEROSIS

#1288
20200345727
2020-11-05

MODULATORS OF THE INTEGRATED STRESS PATHWAY

#1289
20200345583
2020-11-05

Preservative removal from eye drops

#1290
20200339598
2020-10-29

Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity

#1291
20200330462
2020-10-22

Method for treating gonorrhea with (2R)-2-({4-[(3,4-dihydro-2H-pyrano[2,3-C]pyridin-6-ylmethyl)amino]-1-piperidinyl}methyl)-1,2-dihydro-3H,8H-2A,5,8A-triazaacenaphthylene-3,8-dione

#1292
20200330461
2020-10-22

Imidazopyrazine inhibitors of Bruton's tyrosine kinase

#1293
20200330460
2020-10-22

Methods for Treating HCV

#1294
20200330459
2020-10-22

METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF AGE-RELATED CARDIOMETABOLIC DISEASES

#1295
20200330390
2020-10-22

Drug delivery system

#1296
20200325542
2020-10-15

Prognosis method of multiple myeloma

#1297
20200323894
2020-10-15

Combination formulation of three antiviral compounds

#1298
20200323846
2020-10-15

Compositions and methods for preparing and using mitochondrial uncouplers

#1299
20200323773
2020-10-15

FOOD AND BEVERAGE COMPOSITIONS COMPRISING PDE5 INHIBITORS

#1300
20200317714
2020-10-08

Cyclic peroxides as prodrugs for selective delivery of agents

#1301
20200317682
2020-10-08

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[l,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

#1302
20200316072
2020-10-08

COMPOUNDS FOR USE IN REGULATING FOLLICLE MATURATION

#1303
20200316051
2020-10-08

TLR7/8 ANTAGONISTS AND USES THEREOF

#1304
20200316035
2020-10-08

Therapeutic heterocyclic compounds

#1305
20200306247
2020-10-01

Pharmaceutical capsule compositions comprising lumateperone mono-tosylate

#1306
20200306246
2020-10-01

Low-dose triple combination formulation

#1307
20200299301
2020-09-24

Dosage form compositions comprising an inhibitor of Bruton's tyrosine kinase

#1308
20200297692
2020-09-24

SGLT-2 INHIBITORS FOR TREATING METABOLIC DISORDERS IN PATIENTS WITH RENAL IMPAIRMENT OR CHRONIC KIDNEY DISEASE

#1309
20200291040
2020-09-17

PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

#1310
20200291039
2020-09-17

4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors

#1311
20200289516
2020-09-17

Annulated glycosidase inhibitors

#1312
20200289506
2020-09-17

COMBINATION OF A BTK INHIBITOR AND AN INHIBITOR OR CDK9 TO TREAT CANCER

#1313
20200289420
2020-09-17

PHARMACEUTICAL COMPOSITIONS FOR TREATING DIABETES AND PREPARATION METHOD THEREOF

#1314
20200282016
2020-09-10

Endoparasitic depsipeptides

#1315
20200277285
2020-09-03

INHIBITORS OF JUN N-TERMINAL KINASE

#1316
20200276206
2020-09-03

Heterocyclic compounds as pad inhibitors

#1317
20200276193
2020-09-03

Bromocriptine formulations

#1318
20200276127
2020-09-03

METHOD FOR PRODUCING BEADS

#1319
20200270252
2020-08-27

Fused indazole pyridone compounds as antivirals

#1320
20200268859
2020-08-27

Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy

#1321
20200262836
2020-08-20

Inhibitors of hepatitis C virus replication

#1322
20200261469
2020-08-20

Mitofusin activators and uses thereof

#1323
20200261450
2020-08-20

6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

#1324
20200261449
2020-08-20

Pharmaceutical compositions of nilotinib

#1325
20200261448
2020-08-20

Combination therapy for treating pulmonary hypertension

#1326
20200255437
2020-08-13

Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate

#1327
20200253970
2020-08-13

Method of treating metabolic disorders and depression with dopamine receptor agonists

#1328
20200253969
2020-08-13

Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors

#1329
20200253968
2020-08-13

Solid pharmaceutical compositions for treating HCV

#1330
20200253954
2020-08-13

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

#1331
20200247814
2020-08-06

Hetero-halo inhibitors of histone deacetylase

#1332
20200247806
2020-08-06

Organic compounds

#1333
20200246559
2020-08-06

Heating unit for use in a drug delivery device

#1334
20200246460
2020-08-06

BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same

#1335
20200246366
2020-08-06

Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

#1336
20200246364
2020-08-06

MEDICAL APPLICATION OF COMPOSITION OF FRUCTOSE-1,6-BISPHOSPHATE AND BLOOD CONCENTRATION STABILIZER THEREOF

#1337
20200246336
2020-08-06

Methods of increasing lacrimal proteins

#1338
20200246335
2020-08-06

Sleep improving agent

#1339
20200239480
2020-07-30

CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF

#1340
20200239458
2020-07-30

Inhibitors of protein kinases

#1341
20200239434
2020-07-30

Antibacterial compounds

#1342
20200237875
2020-07-30

FORMULATIONS AND METHODS FOR TREATMENT OF FIBROMYALGIA AND RELATED MYOFASCIAL PAIN DISORDERS

#1343
20200237769
2020-07-30

Treatment of erectile dysfunction and other indications

#1344
20200237749
2020-07-30

Extended release compositions of opioid antagonists and phosphodiesterase 5 inhibitors

#1345
20200230158
2020-07-23

Methods and materials for treating calcific aortic valve stenosis

#1346
20200230147
2020-07-23

Antiviral therapy

#1347
20200222544
2020-07-16

LINEAR POLYSACCHARIDE BASED FILM PRODUCTS

#1348
20200222411
2020-07-16

Uses of DPP IV inhibitors

#1349
20200222399
2020-07-16

NK-3 receptor antagonists for therapeutic treatment of leptin-related disease

#1350
20200222398
2020-07-16

SURVIVIN-TARGETING ANTI-TUMOR AGENTS AND USES THEREOF

#1351
20200222397
2020-07-16

Methods for Treating HCV

#1352
20200222333
2020-07-16

MESOSCALE NANOPARTICLES FOR SELECTIVE TARGETING TO THE KIDNEY AND METHODS OF THEIR THERAPEUTIC USE

#1353
20200215153
2020-07-09

CANCER TREATMENT AND/OR PREVENTION THROUGH REGULATION OF UBIQUITINATION

#1354
20200215063
2020-07-09

SOLID ORAL FILM DOSAGE FORMS AND METHODS FOR MAKING SAME

#1355
20200215062
2020-07-09

Substituted pyrido[1,2-a]pyrrolo[1,2-d]pyrazines for treating viral infections

#1356
20200215060
2020-07-09

Antiproliferative compounds and second active agents for combined use

#1357
20200214990
2020-07-09

Tadalafil orally dissolving film and preparation method thereof

#1358
20200214976
2020-07-09

SELF-GELLING SOLUTIONS FOR ADMINISTRATION OF THERAPEUTICS TO THE INNER EAR

#1359
20200206221
2020-07-02

BETA-AMINO HETEROCYCLIC DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES

#1360
20200197322
2020-06-25

Compositions and methods for treatment of erectile disfunction

#1361
20200190449
2020-06-18

ENRICHED ALCOHOLIC BEVERAGES

#1362
20200188419
2020-06-18

COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS

#1363
20200188410
2020-06-18

CXCR7 inhibitors for the treatment of cancer

#1364
20200188370
2020-06-18

ALK5 inhibitors

#1365
20200188322
2020-06-18

Use of cannabidiol in treatment of pulmonary hypertension

#1366
20200181158
2020-06-11

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

#1367
20200181154
2020-06-11

PYRAZOLE CARBOXAMIDE COMPOUNDS AND METHODS OF USE

#1368
20200179379
2020-06-11

INTRANASAL DHE FOR THE TREATMENT OF HEADACHE

#1369
20200179378
2020-06-11

Compositions, devices, and methods for treating or preventing headaches

#1370
20200179377
2020-06-11

Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor

#1371
20200179345
2020-06-11

PARASITICIDAL ORAL VETERINARY COMPOSITIONS COMPRISING SYSTEMICALLY-ACTING ACTIVE AGENTS, METHODS AND USES THEREOF

#1372
20200172525
2020-06-04

Compounds and pharmaceutical compositions containing at least one of the compounds

#1373
20200172492
2020-06-04

Pharmaceutical compound

#1374
20200171132
2020-06-04

METHODS OF INHIBITING FUNGAL CERAMIDE SYNTHASE FOR TREATMENT OF CRYPTOCOCCUS NEOFORMANS INFECTION

#1375
20200171037
2020-06-04

THERAPEUTIC REGIMEN

#1376
20200171032
2020-06-04

METHODS AND MEDICAL USES

#1377
20200163961
2020-05-28

Bicyclic compounds and methods for their use in treating autism

#1378
20200157113
2020-05-21

Pyrazole derivatives useful as 5-lipoxygenase activating protein (FLAP) inhibitors

#1379
20200157111
2020-05-21

Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine

#1380
20200147079
2020-05-14

Regimens for treating HIV infections and AIDS

#1381
20200147078
2020-05-14

Theranostic agents

#1382
20200147003
2020-05-14

Compositions and methods for treatment of erectile dysfunction

#1383
20200147002
2020-05-14

Compositions and methods for treatment of erectile disfunction

#1384
20200140462
2020-05-07

Fused heterocyclic compound

#1385
20200140447
2020-05-07

Substituted indole Mcl-1 inhibitors

#1386
20200138909
2020-05-07

Glucokinase activator compositions for the treatment of diabetes

#1387
20200138845
2020-05-07

Combination Drug Therapy

#1388
20200138812
2020-05-07

LIVER X RECEPTOR MODULATORS

#1389
20200138811
2020-05-07

Sulfonamide derivatives as JAK inhibitors

#1390
20200138705
2020-05-07

PECTIN GUMMY COMPOSTION AND METHODS OF MAKING AND USING THEREOF

#1391
20200138704
2020-05-07

GELATIN GUMMY COMPOSTION AND METHODS OF MAKING AND USING THEREOF

#1392
20200129583
2020-04-30

COMPOSITION FOR TREATING ACUTE URINARY RETENTION

#1393
20200124600
2020-04-23

METHODS OF TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES

#1394
20200121677
2020-04-23

SUBSTITUTED 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZINES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

#1395
20200121676
2020-04-23

Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection

#1396
20200115381
2020-04-16

Dihydropyrimidine compounds and uses thereof in medicine

#1397
20200113896
2020-04-16

METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY

#1398
20200113892
2020-04-16

Substituted tetrahydroquinolinone compounds as ROR gamma modulators

#1399
20200113879
2020-04-16

Fused tricyclic compounds and uses thereof in medicine

#1400
20200113823
2020-04-16

Tablets with improved acceptance and good storage stability

#1401
20200108061
2020-04-09

Parenteral unit dosage form of dihydroergotamine

#1402
20200102310
2020-04-02

Pharmaceutical compositions comprising 4-(6BR,10AS)-3-methyl-2,3,6B,9,10,10A-hexahydro-1h, 7H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-1-(4-fluorophenyl)butan-1-one and methods of treating conditions of the central nervous system

#1403
20200101142
2020-04-02

PDE5 compositions and methods for immunotherapy

#1404
20200101068
2020-04-02

Heteroaryl Derivatives as PARP Inhibitors

#1405
20200101059
2020-04-02

Treatment of pemphigus

#1406
20200101008
2020-04-02

Oral film formulation for modulating absorption profile

#1407
20200088732
2020-03-19

METHODS FOR THE DIAGNOSIS AND TREATMENT OF PANCREATIC DUCTAL ADENOCARCINOMA

#1408
20200087302
2020-03-19

Nitrogen-containing heterocycle and carbocycle derivatives having TrkA inhibitory activity

#1409
20200085819
2020-03-19

APPLICATION OF 5-HT6 RECEPTOR ANTAGONISTS FOR THE ALLEVIATION OF COGNITIVE DEFICITS OF DOWN SYNDROME

#1410
20200085818
2020-03-19

TADALAFIL FREE BASE-CONTAINING FILM DOSAGE FORM CONTAINING POLYETHYLENE GLYCOL-BASED POLYMER AND/OR VINYL PYRROLIDONE-BASED POLYMER AS DISPERSION STABILIZER

#1411
20200079774
2020-03-12

Tyrosine amide derivatives as Rho-Kinase inhibitors

#1412
20200079744
2020-03-12

Methods using HDAC11 inhibitors

#1413
20200069796
2020-03-05

Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, a PD-1 Inhibitor, and/or a PD-L1 Inhibitor

#1414
20200069715
2020-03-05

BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES

#1415
20200069691
2020-03-05

HETEROCYCLIC COMPOUNDS AS HIV PROTEASE INHIBITORS

#1416
20200069683
2020-03-05

Pharmaceutical capsule compositions comprising lumateperone mono-tosylate

#1417
20200069668
2020-03-05

Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor

#1418
20200069658
2020-03-05

COMBINATION THERAPY FOR PULMONARY HYPERTENSION

#1419
20200069591
2020-03-05

Pharmaceutical preparation and method for its manufacture

#1420
20200062769
2020-02-27

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS

#1421
20200062753
2020-02-27

6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

#1422
20200061073
2020-02-27

Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof

#1423
20200061072
2020-02-27

COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION

#1424
20200061058
2020-02-27

PHARMACEUTICAL FORMULATION CONTAINING TADALAFIL

#1425
20200060991
2020-02-27

METHODS FOR THE TREATMENT OF ERECTILE DYSFUNCTION USING FISPEMIFENE

#1426
20200055873
2020-02-20

Nitrogen-containing tricyclic derivatives having HIV replication inhibitory activity

#1427
20200055859
2020-02-20

INHIBITORS OF BRUTONS TYROSINE KINASE

#1428
20200054643
2020-02-20

FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS

#1429
20200054629
2020-02-20

Therapeutic agent composition and method of use, for treatment of mild congnitive impairment, depression, and psychological disorders

#1430
20200054623
2020-02-20

Chemokine CXCR4 receptor modulators and uses related thereto

#1431
20200054598
2020-02-20

SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease

#1432
20200046713
2020-02-13

TREATMENT OF GENOTYPED DIABETIC PATIENTS WITH DPP-IV INHIBITORS SUCH AS LINAGLIPTIN

#1433
20200046710
2020-02-13

Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions

#1434
20200046696
2020-02-13

TREATMENT OF CANCER WITH SMG1-INHIBITORS

#1435
20200039972
2020-02-06

INHIBITORS OF JUN N-TERMINAL KINASE

#1436
20200038401
2020-02-06

Therapeutic Compositions

#1437
20200038368
2020-02-06

Methods of treating or reducing the risk of cardiovascular events and related diseases using SGLT-2 inhibitors

#1438
20200030275
2020-01-30

ENHANCER OF PHOTODYNAMIC EFFECT IN ALA-PDT OR ALA-PDD

#1439
20200022981
2020-01-23

Compositions and methods

#1440
20200022978
2020-01-23

Combination of a DNA condensation-inducing compound and an Eis inhibitor for antibiotic treatment

#1441
20200022930
2020-01-23

Metformin glycinate, pharmaceutical compositions comprising the same, and methods of using the same

#1442
20200017499
2020-01-16

Compositions and methods

#1443
20200017458
2020-01-16

Compounds and compositions for inhibition of FASN

#1444
20200009134
2020-01-09

Method and Compound for Modifying Circadian Clock

#1445
20200009099
2020-01-09

COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF SCHISTOSOMIASIS

#1446
20200002353
2020-01-02

Heteroaryl estrogen receptor modulators and uses thereof

#1447
20200002326
2020-01-02

Sulfoximine glycosidase inhibitors

#1448
20200002318
2020-01-02

AZETIDINYLOXYPHENYLPYRROLIDINE COMPOUNDS

#1449
20200002281
2020-01-02

N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease

#1450
20200000811
2020-01-02

METHODS OF USE OF INHIBITORS OF PHOSPHODIESTERASES AND MODULATORS OF NITRIC OXIDE, REACTIVE OXYGEN SPECIES, AND METALLOPROTEINASES IN THE TREATMENT OF PEYRONIE'S DISEASE, ARTERIOSCLEROSIS AND OTHER FIBROTIC DISEASES

#1451
20200000774
2020-01-02

CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS WITH ENHANCED EFFICACY

#1452
20190389815
2019-12-26

Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof

#1453
20190388435
2019-12-26

PHARMACEUTICAL FORMULATIONS AND USES THEREOF IN THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION

#1454
20190388420
2019-12-26

Tumor-treating pharmaceutical composition

#1455
20190388419
2019-12-26

Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine

#1456
20190388418
2019-12-26

Amorphous solid dispersions

#1457
20190388415
2019-12-26

Substituted dihydrobenzofuran glycosidase inhibitors

#1458
20190385719
2019-12-19

Methods for treating erectile dysfunction with a cGMP-specific phosphodiesterase 5 inhibitor pharmaceutical composition

#1459
20190382405
2019-12-19

Crystal form of ACP-196, preparation method therefor and pharmaceutical composition thereof

#1460
20190381044
2019-12-19

BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment

#1461
20190381006
2019-12-19

Use of a rotifer-derived compound and its analogs for preventing schistosomiasis

#1462
20190375726
2019-12-12

Compounds for the treatment of HIV

#1463
20190374548
2019-12-12

Amino, amido and heterocyclic compounds as modulators of RAGE activity and uses thereof

#1464
20190374543
2019-12-12

Therapeutic Combinations of an Antifolate and a BTK Inhibitor

#1465
20190374539
2019-12-12

Therapeutic combinations of a MEK inhibitor and a BTK inhibitor

#1466
20190374475
2019-12-12

Soft gelatin capsules containing hydroxypropyl beta cyclodextrin with high stability

#1467
20190367631
2019-12-05

Anti-MSR1 antibodies and methods of use thereof

#1468
20190367531
2019-12-05

Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use

#1469
20190367524
2019-12-05

Imidazopyrazine compounds, preparation methods and uses thereof

#1470
20190367495
2019-12-05

Antidiabetic heterocyclic compounds

#1471
20190365750
2019-12-05

Method of reducing pulmonary exacerbations in respiratory disease patients

#1472
20190365748
2019-12-05

Inhibitors of hepatitis C virus

#1473
20190365661
2019-12-05

Sublingual films

#1474
20190359595
2019-11-28

INDOLIZINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

#1475
20190358237
2019-11-28

Bicyclic bromodomain inhibitors

#1476
20190358231
2019-11-28

Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases

#1477
20190358225
2019-11-28

Substituted fused heteroaromatic compounds as kinase inhibitors and the use thereof

#1478
20190358156
2019-11-28

Fast disintegrating pharmaceutical composition

#1479
20190352272
2019-11-21

Bridged bicycloalkyl-substituted aminothiazoles and their methods of use

#1480
20190350880
2019-11-21

Particulate materials

#1481
20190345151
2019-11-14

Ferroportin inhibitors

#1482
20190343868
2019-11-14

Benzimidazoles that enhance the activity of oligonucleotides

#1483
20190343838
2019-11-14

KRAS G12C inhibitors and methods of using the same

#1484
20190343833
2019-11-14

Bromocriptine formulations

#1485
20190337949
2019-11-07

Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma

#1486
20190330698
2019-10-31

DIABETES POLYGENIC RISK SCORE

#1487
20190330233
2019-10-31

Benzopiperazine compositions as BET bromodomain inhibitors

#1488
20190330232
2019-10-31

Compositions and methods of regulating glucose homeostasis and insulin action

#1489
20190330189
2019-10-31

ANTIBACTERIAL COMPOUNDS

#1490
20190328900
2019-10-31

ANTIBODY-DRUG CONJUGATES AND THERAPEUTIC METHODS USING THE SAME

#1491
20190328745
2019-10-31

Methods of treating bipolar disorder

#1492
20190328733
2019-10-31

Combination Therapy for Male Sexual Dysfunction

#1493
20190322718
2019-10-24

PAC1 receptor agonists (MAXCAPS) and uses thereof

#1494
20190322677
2019-10-24

Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carb oxamide and solid state forms thereof

#1495
20190322666
2019-10-24

FUSED TRICYCLIC HETEROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS

#1496
20190322656
2019-10-24

Compound, and production method thereof, and methods of treatment using the compound

#1497
20190321360
2019-10-24

Hepatitis B antiviral agents

#1498
20190315847
2019-10-17

Therapeutic combinations using IGF1R pathway inhibitors, and methods to predict anti-IGF1R therapeutic efficacy

#1499
20190315769
2019-10-17

Tetracyclic heterocycle compounds useful as HIV integrase inhibitors

#1500
20190315761
2019-10-17

Processes for the preparation of (3S,4R)-3,ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof